Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) to present at the 6th annual Evercore ISI HealthCONx Conference on November 28th, 2023. The company focuses on acquiring, developing, and commercializing therapies for rare and orphan diseases. Visit the corporate website for webcast links and more details.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to present at the 6^th annual Evercore ISI HealthCONx Conference on Tuesday, November 28^th 2023 at 3:25 pm ET, as well as 1x1 meetings.

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes three investigational treatments for debilitating liver diseases. The LIVMARLI development program includes the Phase 2b EMBARK study for biliary atresia. Mirum’s second investigational IBAT inhibitor is volixibat, which is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120253689/en/

Investor Contacts:

Andrew McKibben

investors@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When is Mirum Pharmaceuticals presenting at the Evercore ISI HealthCONx Conference?

Mirum Pharmaceuticals is scheduled to present at the 6th annual Evercore ISI HealthCONx Conference on Tuesday, November 28th, 2023 at 3:25 pm ET.

What is the focus of Mirum Pharmaceuticals, Inc.?

Mirum Pharmaceuticals is focused on identifying, acquiring, developing, and commercializing novel therapies for rare and orphan diseases.

Where can I find webcast links and additional information about Mirum Pharmaceuticals' presentation?

You can find webcast links and additional information on Mirum Pharmaceuticals' corporate website in the Investors and Media section.